MicroRNA-222-3p Targeting ANGPTL2 Inhibits Migration In Ovarian Epithelial Cancer Cells

Epithelial ovarian cancer is the most common ovarian tumor,with the first mortality rate among gynecologic cancer,and is prone to drug resistance and recurrence during treatment.The survival rate is lower than other gynecological cancers,so find new and more effective targeted drugs or therapeutic pathways to make the benefit of cancer patients is an urgent problem to be solved.miR-222-3p belongs to the miR-221 / 222 family.Patients with high levels of miR-222-3p have longer overall survival rates in epithelial ovarian cancer,but it is not clear which genes affect miR-222-3p to regulate migration.Angiopoietin-like 2(ANGPTL2)is a secreted glycoprotein that has a similar structure to angiogenin and plays an important role in the inflammatory response.It is found to be highly expressed in many tumors such as esophageal cancer,gastric cancer,pancreatic cancer,colorectal cancer and non-small cell lung cancer.It promotes tumor growth and metastasis through multiple aspects,such as promoting tumor cell invasion and migration and tumor tissueangiogenesis.One of the signs of poor patient prognosis.In this paper,dual-luciferase reporter system to demonstrate that miR-222-3p directly targets ANGPTL2.The interaction between miR-222-3p and ANGPTL2 and their role in the migration of ovarian epithelial cancer cells were studied in HO8910 and HO8910 PM cells by overexpression and down-regulation of miR-222-3p expression levels.For the new discovery that ANGPTL2 promotes ovarian epithelial cancer cell migration,bioinformatics analysis indicates that EDNRA may be downstream of the ANGPTL2 gene regulating cancer cell migration.We also used a histopathological technique and correlation analysis of clinical records to obtain a poor prognosis for patients with high-level ANGPTL2 ovarian epithelial cancer.These results not only provide a molecular basis for elucidating the mechanism of miR-222-3p regulating the migration of ovarian epithelial cancer cells,but also provide new targets for the treatment of ovarian epithelial cancer.